PodParley PodParley
PodParley
MPR Weekly Dose 108 - OTC Treatment Shows Benefit in COVID-19; Emergency Use Granted to Antibody; Parkinson Disease Tx Available; Veklury Study Results; Safety Concern for Ketamine episode artwork

EPISODE · Feb 18, 2022 · 14 MIN

MPR Weekly Dose 108 - OTC Treatment Shows Benefit in COVID-19; Emergency Use Granted to Antibody; Parkinson Disease Tx Available; Veklury Study Results; Safety Concern for Ketamine

from MPR Weekly Dose

This week in COVID related news, a heartburn medication shows benefit in patients; Bebtelovimab is authroized; Veklury is shown to retain antiviral activity against variants. Away from COVID, a functionally scored carbidopa/levodopa tablet is now available for Parkinson disease, and the FDA issue a ketamine compounding warning.

Episode metadata supplied by the publisher feed · Published Feb 18, 2022

Embed this episode

Ready to play

MPR Weekly Dose 108 - OTC Treatment Shows Benefit in COVID-19; Emergency Use Granted to Antibody; Parkinson Disease Tx Available; Veklury Study Results; Safety Concern for Ketamine

0:00 14:39

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 14 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on February 18, 2022.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!